chr11-61397942-T-G
Position:
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PVS1_ModeratePM2PP5_Very_Strong
The NM_001173990.3(TMEM216):āc.398T>Gā(p.Leu133Ter) variant causes a stop gained change. The variant allele was found at a frequency of 0.000013 in 1,613,856 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (ā ā ).
Frequency
Genomes: š 0.000026 ( 0 hom., cov: 32)
Exomes š: 0.000012 ( 0 hom. )
Consequence
TMEM216
NM_001173990.3 stop_gained
NM_001173990.3 stop_gained
Scores
3
3
1
Clinical Significance
Conservation
PhyloP100: 6.72
Genes affected
TMEM216 (HGNC:25018): (transmembrane protein 216) This locus encodes a transmembrane domain-containing protein. Mutations at this locus have been associated with Meckel-Gruber Syndrome Type 2, and Joubert Syndrome 2, also known as Cerebello-oculorenal Syndrome 2. [provided by RefSeq, Aug 2010]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 12 ACMG points.
PVS1
Loss of function variant, product does not undergo nonsense mediated mRNA decay. Variant is located in the 3'-most 50 bp of the penultimate exon, not predicted to undergo nonsense mediated mRNA decay. Fraction of 0.0913 CDS is truncated, and there are 1 pathogenic variants in the truncated region.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 11-61397942-T-G is Pathogenic according to our data. Variant chr11-61397942-T-G is described in ClinVar as [Likely_pathogenic]. Clinvar id is 217704.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr11-61397942-T-G is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
TMEM216 | NM_001173990.3 | c.398T>G | p.Leu133Ter | stop_gained | 4/5 | ENST00000515837.7 | NP_001167461.1 | |
TMEM216 | NM_001173991.3 | c.398T>G | p.Leu133Ter | stop_gained | 4/5 | NP_001167462.1 | ||
TMEM216 | NM_016499.6 | c.215T>G | p.Leu72Ter | stop_gained | 4/5 | NP_057583.2 | ||
TMEM216 | NM_001330285.2 | c.215T>G | p.Leu72Ter | stop_gained | 4/5 | NP_001317214.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
TMEM216 | ENST00000515837.7 | c.398T>G | p.Leu133Ter | stop_gained | 4/5 | 2 | NM_001173990.3 | ENSP00000440638 | P4 |
Frequencies
GnomAD3 genomes AF: 0.0000263 AC: 4AN: 152228Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
4
AN:
152228
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.00000803 AC: 2AN: 249212Hom.: 0 AF XY: 0.00000740 AC XY: 1AN XY: 135212
GnomAD3 exomes
AF:
AC:
2
AN:
249212
Hom.:
AF XY:
AC XY:
1
AN XY:
135212
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000116 AC: 17AN: 1461628Hom.: 0 Cov.: 35 AF XY: 0.0000138 AC XY: 10AN XY: 727114
GnomAD4 exome
AF:
AC:
17
AN:
1461628
Hom.:
Cov.:
35
AF XY:
AC XY:
10
AN XY:
727114
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000263 AC: 4AN: 152228Hom.: 0 Cov.: 32 AF XY: 0.0000134 AC XY: 1AN XY: 74380
GnomAD4 genome
AF:
AC:
4
AN:
152228
Hom.:
Cov.:
32
AF XY:
AC XY:
1
AN XY:
74380
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ExAC
AF:
AC:
1
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:6
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Joubert syndrome 2 Pathogenic:2
Likely pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Apr 04, 2024 | Variant summary: TMEM216 c.398T>G (p.Leu133X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. The variant allele was found at a frequency of 8e-06 in 249212 control chromosomes (gnomAD). c.398T>G has been reported in the literature as a compound heterozygous genotype in at least one individual affected with Joubert Syndrome 2 (example, Valente_2010, Bachmann-Gagescu_2015). To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 26092869, 20512146). ClinVar contains an entry for this variant (Variation ID: 217704). Based on the evidence outlined above, the variant was classified as likely pathogenic. - |
Pathogenic, criteria provided, single submitter | research | UW Hindbrain Malformation Research Program, University of Washington | Feb 23, 2015 | - - |
Joubert syndrome 2;C1864148:Meckel syndrome, type 2 Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Apr 11, 2022 | - - |
TMEM216-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Jul 13, 2024 | The TMEM216 c.398T>G variant is predicted to result in premature protein termination (p.Leu133*). This variant has been identified in two presumably unrelated individuals with Joubert syndrome and related disorders (Valente et al. 2010. PubMed ID: 20512146; Bachmann-Gagescu et al. 2015. PubMed ID: 26092869). This variant is reported in 0.0018% of alleles in individuals of European (Non-Finnish) descent in gnomAD. Nonsense variants in TMEM216 are expected to be pathogenic. This variant is interpreted as pathogenic. - |
not provided Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Oct 29, 2018 | The L133X variant in the TMEM216 gene has been reported previously, along with a TMEM216 missense variant, in individuals with clinical findings of Joubert syndrome (Valente et al., 2010; Bachmann-Gagescu et al., 2015). This variant is predicted to cause loss of normal protein function through protein truncation. The L133X variant is not observed at a significant frequency in large population cohorts (Lek et al., 2016). We interpret L133X as a likely pathogenic variant. - |
Familial aplasia of the vermis Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jul 14, 2023 | This sequence change creates a premature translational stop signal (p.Leu133*) in the TMEM216 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 13 amino acid(s) of the TMEM216 protein. This variant is present in population databases (rs755459875, gnomAD 0.002%). This premature translational stop signal has been observed in individual(s) with Joubert syndrome (PMID: 20512146, 26092869). ClinVar contains an entry for this variant (Variation ID: 217704). For these reasons, this variant has been classified as Pathogenic. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Pathogenic
D
MutationTaster
Benign
D;D;D
Vest4
GERP RS
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at